<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font18 { font-size : 18; } .font19 { font-size : 19; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font25">the </span>
   <span class="font19">with </span>
   <span class="font18">for </span>
   <span class="font15">patients </span>
   <span class="font14">[]. </span>
   <span class="font14">COVID- </span>
   <span class="font13">clinical </span>
   <span class="font13">are </span>
   <span class="font13">that </span>
   <span class="font12">CRS </span>
   <span class="font12">from </span>
   <span class="font12">cells </span>
   <span class="font12">IL- </span>
   <span class="font12">{background </span>
   <span class="font12">The </span>
   <span class="font12">severe </span>
   <span class="font12">may </span>
   <span class="font12">cell </span>
   <span class="font12">has </span>
   <span class="font12">treatment </span>
   <span class="font11">have </span>
   <span class="font11">immune </span>
   <span class="font11">margin </span>
   <span class="font11">respiratory </span>
   <span class="font11">been </span>
   <span class="font11">cytokine </span>
   <span class="font11">not </span>
   <span class="font11">{border-style </span>
   <span class="font11">other </span>
   <span class="font11">after </span>
   <span class="font11">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">therapy </span>
   <span class="font11">(â€") </span>
   <span class="font11">including </span>
   <span class="font11">inflammatory </span>
   <span class="font11">syndrome </span>
   <span class="font11">tocilizumab </span>
   <span class="font11">against </span>
   <span class="font11">associated </span>
   <span class="font11">such </span>
   <span class="font11">use </span>
   <span class="font11">were </span>
   <span class="font11">Med </span>
   <span class="font11">currently </span>
   <span class="font11">described </span>
   <span class="font11">disease </span>
   <span class="font11">virus </span>
   <span class="font11">/â€" </span>
   <span class="font11">IRIS </span>
   <span class="font11">acute </span>
   <span class="font11">being </span>
   <span class="font11">this </span>
   <span class="font10">This </span>
   <span class="font10">[], </span>
   <span class="font10">administration </span>
   <span class="font10">days </span>
   <span class="font10">infection </span>
   <span class="font10">its </span>
   <span class="font10">potential </span>
   <span class="font10">receptor </span>
   <span class="font10">several </span>
   <span class="font10">therapies </span>
   <span class="font10">trials </span>
   <span class="font10">viral </span>
   <span class="font10">was </span>
   <span class="font10">within </span>
   <span class="font10">(.â€".) </span>
   <span class="font10">(â€".) </span>
   <span class="font10">Cell </span>
   <span class="font10">Engl </span>
   <span class="font10">Table </span>
   <span class="font10">also </span>
   <span class="font10">can </span>
   <span class="font10">cellular </span>
   <span class="font10">coronavirus </span>
   <span class="font10">data </span>
   <span class="font10">phase </span>
   <span class="font10">safety </span>
   <span class="font10">study </span>
   <span class="font10">therapeutic </span>
   <span class="font10">well </span>
   <span class="font10">which </span>
   <span class="font10">who </span>
   <span class="font10">COVID-. </span>
   <span class="font10">SARS-CoV- </span>
   <span class="font10">Society </span>
   <span class="font10">allogeneic </span>
   <span class="font10">antiviral </span>
   <span class="font10">but </span>
   <span class="font10">high </span>
   <span class="font10">hospitalized </span>
   <span class="font10">human </span>
   <span class="font10">hyperimmune </span>
   <span class="font10">information </span>
   <span class="font10">levels </span>
   <span class="font10">lung </span>
   <span class="font10">most </span>
   <span class="font10">novel </span>
   <span class="font10">px; </span>
   <span class="font10">related </span>
   <span class="font10">release </span>
   <span class="font10">sHLH </span>
   <span class="font10">studies </span>
   <span class="font10">these </span>
   <span class="font10">{font-family </span>
   <span class="font10">HLH </span>
   <span class="font10">However, </span>
   <span class="font10">MSC </span>
   <span class="font10">MSCs </span>
   <span class="font10">activity </span>
   <span class="font10">approved </span>
   <span class="font10">cells, </span>
   <span class="font10">conditions </span>
   <span class="font10">could </span>
   <span class="font10">dose </span>
   <span class="font10">efficacy </span>
   <span class="font10">features </span>
   <span class="font10">font-size </span>
   <span class="font10">more </span>
   <span class="font10">one </span>
   <span class="font10">plasma </span>
   <span class="font10">research </span>
   <span class="font10">response </span>
   <span class="font10">responses </span>
   <span class="font10">there </span>
   <span class="font10">and/or </span>
   <span class="font10">day </span>
   <span class="font10">double; </span>
   <span class="font10">drugs </span>
   <span class="font10">hematopoietic </span>
   <span class="font10">hosts </span>
   <span class="font10">mortality </span>
   <span class="font10">provide </span>
   <span class="font10">severity </span>
   <span class="font10">some </span>
   <span class="font10">stem </span>
   <span class="font10">than </span>
   <span class="font10">their </span>
   <span class="font10">trial </span>
   <span class="font10">used </span>
   <span class="font10">vitro </span>
   <span class="font10">when </span>
   <span class="font10">without </span>
   <span class="font10">(nÂ </span>
   <span class="font10">CAR-T </span>
   <span class="font10">Elsevier </span>
   <span class="font10">Gene </span>
   <span class="font10">Grade </span>
   <span class="font10">Requiring </span>
   <span class="font10">T-cell </span>
   <span class="font10">Temperature </span>
   <span class="font10">Therapy </span>
   <span class="font10">activation </span>
   <span class="font10">adverse </span>
   <span class="font10">antibody </span>
   <span class="font10">available </span>
   <span class="font10">blood </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">both </span>
   <span class="font10">cells. </span>
   <span class="font10">combination </span>
   <span class="font10">convalescent </span>
   <span class="font10">criteria </span>
   <span class="font10">due </span>
   <span class="font10">elevated </span>
   <span class="font10">evaluation </span>
   <span class="font10">given </span>
   <span class="font10">higher </span>
   <span class="font10">important </span>
   <span class="font10">increase </span>
   <span class="font10">infected </span>
   <span class="font10">limited </span>
   <span class="font10">nasal </span>
   <span class="font10">observed </span>
   <span class="font10">pandemic </span>
   <span class="font10">patient </span>
   <span class="font10">range </span>
   <span class="font10">recently </span>
   <span class="font10">role </span>
   <span class="font10">serum </span>
   <span class="font10">solid; </span>
   <span class="font10">specific </span>
   <span class="font10">syndromes </span>
   <span class="font10">three </span>
   <span class="font10">treatments </span>
   <span class="font10">vesicles </span>
   <span class="font10">virus, </span>
   <span class="font10">virus-specific </span>
   <span class="font10">viruses </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">â‰¥Â°C </span>
   <span class="font10">â€" </span>
   <span class="font10">(Table </span>
   <span class="font10">April </span>
   <span class="font10">COVID-, </span>
   <span class="font10">CRS, </span>
   <span class="font10">Clinical </span>
   <span class="font10">Currently, </span>
   <span class="font10">Cytokine </span>
   <span class="font10">IL-, </span>
   <span class="font10">IRIS. </span>
   <span class="font10">Immunol </span>
   <span class="font10">International </span>
   <span class="font10">MERS </span>
   <span class="font10">Moreover, </span>
   <span class="font10">SARS-CoV </span>
   <span class="font10">These </span>
   <span class="font10">Tocilizumab </span>
   <span class="font10">[,]. </span>
   <span class="font10">[published </span>
   <span class="font10">adult </span>
   <span class="font10">adults </span>
   <span class="font10">ahead </span>
   <span class="font10">anakinra </span>
   <span class="font10">any </span>
   <span class="font10">authors </span>
   <span class="font10">based </span>
   <span class="font10">bold </span>
   <span class="font10">bone </span>
   <span class="font10">care </span>
   <span class="font10">centre </span>
   <span class="font10">cohort </span>
   <span class="font10">common </span>
   <span class="font10">courier; </span>
   <span class="font10">critically </span>
   <span class="font10">current </span>
   <span class="font10">dampen </span>
   <span class="font10">develop </span>
   <span class="font10">distress </span>
   <span class="font10">during </span>
   <span class="font10">each </span>
   <span class="font10">em; </span>
   <span class="font10">evaluating </span>
   <span class="font10">events </span>
   <span class="font10">factor, </span>
   <span class="font10">failure </span>
   <span class="font10">grading </span>
   <span class="font10">hyperinflammatory </span>
   <span class="font10">increased </span>
   <span class="font10">influenza </span>
   <span class="font10">inhibitors </span>
   <span class="font10">laboratory </span>
   <span class="font10">least </span>
   <span class="font10">likely </span>
   <span class="font10">many </span>
   <span class="font10">mild </span>
   <span class="font10">moderate </span>
   <span class="font10">monoclonal </span>
   <span class="font10">multiple </span>
   <span class="font10">online </span>
   <span class="font10">oxygen </span>
   <span class="font10">pathogenesis </span>
   <span class="font10">patients, </span>
   <span class="font10">patients. </span>
   <span class="font10">placebo </span>
   <span class="font10">potentially </span>
   <span class="font10">present </span>
   <span class="font10">protein, </span>
   <span class="font10">pt;} </span>
   <span class="font10">public </span>
   <span class="font10">randomized </span>
   <span class="font10">reconstitution </span>
   <span class="font10">remains </span>
   <span class="font10">requiring </span>
   <span class="font10">resource </span>
   <span class="font10">responsible </span>
   <span class="font10">rheumatoid </span>
   <span class="font10">should </span>
   <span class="font10">signaling </span>
   <span class="font10">soluble </span>
   <span class="font10">storm </span>
   <span class="font10">support </span>
   <span class="font10">supportive </span>
   <span class="font10">therefore, </span>
   <span class="font10">those </span>
   <span class="font10">time </span>
   <span class="font10">tissue </span>
   <span class="font10">treated </span>
   <span class="font10">two </span>
   <span class="font10">type </span>
   <span class="font10">will </span>
  </p>
 </body>
</html>
